TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05639933: Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

Sponsor: Hoth Therapeutics, Inc. · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 152 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,264,200

Rescue Site Savings

+$825,600

Unlock Full NCT05639933 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05639933 Rescue Dossier →